Nanomedicine-based strategies for the treatment of vein graft disease

IF 41.7 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Zhuoming Zhou, Wei Chen, Yihai Cao, Reza Abdi, Wei Tao
{"title":"Nanomedicine-based strategies for the treatment of vein graft disease","authors":"Zhuoming Zhou, Wei Chen, Yihai Cao, Reza Abdi, Wei Tao","doi":"10.1038/s41569-024-01094-y","DOIUrl":null,"url":null,"abstract":"<p>Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40–50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms underlying vein graft disease, nanomedicine-based strategies offer promising opportunities to address this important unmet clinical need. In this Review, we provide deep insight into the latest developments in the rational design and applications of nanoparticles that have the potential to target specific cells during various pathophysiological stages of vein graft disease, including early endothelial dysfunction, intermediate intimal hyperplasia and late-stage accelerated atherosclerosis. Additionally, we underscore the convergence of nanofabricated biomaterials, with a particular focus on hydrogels, external graft support devices and cell-based therapies, alongside bypass surgery to improve local delivery efficiency and therapeutic efficacy. Finally, we provide a specific discussion on the considerations, challenges and novel perspectives for the future clinical translation of nanomedicine for the treatment of vein graft disease.</p>","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"67 1","pages":""},"PeriodicalIF":41.7000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41569-024-01094-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Autologous saphenous veins are the most frequently used conduits for coronary and peripheral artery bypass grafting. However, vein graft failure rates of 40–50% within 10 years of the implantation lead to poor long-term outcomes after bypass surgery. Currently, only a few therapeutic approaches for vein graft disease have been successfully translated into clinical practice. Building on the past two decades of advanced understanding of vein graft biology and the pathophysiological mechanisms underlying vein graft disease, nanomedicine-based strategies offer promising opportunities to address this important unmet clinical need. In this Review, we provide deep insight into the latest developments in the rational design and applications of nanoparticles that have the potential to target specific cells during various pathophysiological stages of vein graft disease, including early endothelial dysfunction, intermediate intimal hyperplasia and late-stage accelerated atherosclerosis. Additionally, we underscore the convergence of nanofabricated biomaterials, with a particular focus on hydrogels, external graft support devices and cell-based therapies, alongside bypass surgery to improve local delivery efficiency and therapeutic efficacy. Finally, we provide a specific discussion on the considerations, challenges and novel perspectives for the future clinical translation of nanomedicine for the treatment of vein graft disease.

Abstract Image

基于纳米药物的静脉移植疾病治疗策略
自体大隐静脉是冠状动脉和外周动脉搭桥术中最常用的导管。然而,静脉移植术后 10 年内的失败率高达 40%-50%,导致搭桥手术后的长期疗效不佳。目前,只有少数针对静脉移植疾病的治疗方法已成功应用于临床实践。过去二十年来,人们对静脉移植生物学和静脉移植疾病的病理生理机制有了更深入的了解,在此基础上,基于纳米药物的策略为解决这一尚未满足的重要临床需求提供了大有可为的机会。在本综述中,我们将深入探讨合理设计和应用纳米粒子的最新进展,这些纳米粒子有可能在静脉移植物疾病的不同病理生理阶段靶向特定细胞,包括早期内皮功能障碍、中期内膜增生和晚期加速动脉粥样硬化。此外,我们还强调了纳米加工生物材料与搭桥手术的融合,特别是水凝胶、外部移植支持装置和细胞疗法,以提高局部输送效率和疗效。最后,我们就纳米医学在未来临床应用于治疗静脉移植物疾病的注意事项、挑战和新视角进行了具体讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Reviews Cardiology
Nature Reviews Cardiology 医学-心血管系统
CiteScore
53.10
自引率
0.60%
发文量
143
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Cardiology aims to be the go-to source for reviews and commentaries in the scientific and clinical communities it serves. Focused on providing authoritative and accessible articles enriched with clear figures and tables, the journal strives to offer unparalleled service to authors, referees, and readers, maximizing the usefulness and impact of each publication. It covers a broad range of content types, including Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives, catering to practising cardiologists and cardiovascular research scientists. Authored by renowned clinicians, academics, and researchers, the content targets readers in the biological and medical sciences, ensuring accessibility across various disciplines. In-depth Reviews offer up-to-date information, while Consensus Statements provide evidence-based recommendations. Perspectives and News & Views present topical discussions and opinions, and the Research Highlights section filters primary research from cardiovascular and general medical journals. As part of the Nature Reviews portfolio, Nature Reviews Cardiology maintains high standards and a wide reach.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信